OnKure Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 45

Employees

  • Stock Symbol
  • OKUR

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.58
  • (As of Tuesday Closing)

OnKure Therapeutics General Information

Description

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Contact Information

Formerly Known As
Reneo Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 6707 Winchester Circle
  • Suite 400
  • Boulder, CO 80301
  • United States
+1 (720)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 6707 Winchester Circle
  • Suite 400
  • Boulder, CO 80301
  • United States
+1 (720)

OnKure Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OnKure Therapeutics Stock Performance

As of 17-Nov-2026, OnKure Therapeutics’s stock price is $2.58. Its current market cap is $106M with 41.2M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.58 $2.75 $2.01 - $5.38 $106M 41.2M 333K -$2.26

OnKure Therapeutics Financials Summary

As of 30-Sep-2026, OnKure Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (63,237) (30,354) 38,716
Revenue 0 0 0 0
EBITDA (65,165) (62,120) (53,724) (36,374)
Net Income (61,852) (59,517) (52,673) (35,311)
Total Assets 167,077 62,117 114,907 35,734
Total Debt 790 549 1,085 674
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OnKure Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore OnKure Therapeutics‘s full profile, request access.

Request a free trial

OnKure Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore OnKure Therapeutics‘s full profile, request access.

Request a free trial

OnKure Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision me
Biotechnology
Boulder, CO
45 As of 2026

Basel, Switzerland
 

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OnKure Therapeutics Competitors (90)

One of OnKure Therapeutics’s 90 competitors is Roche, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Roche Corporation Basel, Switzerland
BeOne Medicines Formerly PE-Backed Beijing, China
Novavax Corporation Gaithersburg, MD
GSK Corporation London, United Kingdom
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
You’re viewing 5 of 90 competitors. Get the full list »

OnKure Therapeutics Patents

OnKure Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026169751-A1 Compounds containing fused tricyclic rings as pi3k inhibitors Pending 07-Feb-2025
WO-2026122515-A1 Quinolizinones as pi3k inhibitors Pending 06-Dec-2024
WO-2026112125-A1 Benzopyridinones as pi3k inhibitors Pending 22-Nov-2024
WO-2025255233-A1 Compounds containing fused tricyclic rings as pi3k inhibitors Pending 07-Jun-2024
WO-2025212360-A1 Isoquinolones as pi3k inhibitors Pending 01-Apr-2024 C07D401/14
To view OnKure Therapeutics’s complete patent history, request access »

OnKure Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OnKure Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore OnKure Therapeutics‘s full profile, request access.

Request a free trial

OnKure Therapeutics Acquisitions (1)

OnKure Therapeutics’s most recent deal was a Merger/Acquisition with Reneo Pharmaceuticals. The deal was made on 04-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Reneo Pharmaceuticals 04-Oct-2024 Merger/Acquisition Drug Discovery
To view OnKure Therapeutics’s complete acquisitions history, request access »

OnKure Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.49 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view OnKure Therapeutics’s complete esg history, request access »

OnKure Therapeutics FAQs

  • When was OnKure Therapeutics founded?

    OnKure Therapeutics was founded in 2011.

  • Where is OnKure Therapeutics headquartered?

    OnKure Therapeutics is headquartered in Boulder, CO.

  • What is the size of OnKure Therapeutics?

    OnKure Therapeutics has 45 total employees.

  • What industry is OnKure Therapeutics in?

    OnKure Therapeutics’s primary industry is Biotechnology.

  • Is OnKure Therapeutics a private or public company?

    OnKure Therapeutics is a Public company.

  • What is OnKure Therapeutics’s stock symbol?

    The ticker symbol for OnKure Therapeutics is OKUR.

  • What is the current stock price of OnKure Therapeutics?

    As of 17-Nov-2026 the stock price of OnKure Therapeutics is $2.58.

  • What is the current market cap of OnKure Therapeutics?

    The current market capitalization of OnKure Therapeutics is $106M.

  • Who are OnKure Therapeutics’s competitors?

    Roche, BeOne Medicines, Novavax, GSK, and Genetix Biotherapeutics are some of the 90 competitors of OnKure Therapeutics.

  • What is OnKure Therapeutics’s annual earnings per share (EPS)?

    OnKure Therapeutics’s EPS for 12 months was -$2.26.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process